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Summary
Objectives: To evaluate the significance of involvement of 
subvalvular apparatus in the outcome of percutaneous 
mitral balloon valvotomy (PMBv) in patients with mitral 
stenosis (MS) and to determine the predictive value of 
chordal length compared with current echocardiographic 
scores.
Methods: Patients with significant MS were selected accord-
ing to the Massachusetts General Hospital score (MGHS). 
Chordal lengths were assessed as additional markers of 
disease. Standard percutaneous valvotomies were performed. 
valve area was assessed post-procedure with follow-up over 
one year. 
Results: Thirty-nine patients were prospectively studied. 
valve area increased from a mean (SD) 0.97 (0.26) cm² 
to 1.52 (0.38) cm² with procedural success in 31 (79.5%) 
patients. There was no correlation (r 5 0.09) between the 
MGHS and final valve area (fvA). There was a positive 
correlation between anterior chordal length and fvA (r 5 
0.66; p 5 0.01). An fvA ≥ 1.5 cm² was associated with higher 
mean chordal lengths (p 5 0.01). A positive correlation was 
seen between valve area pre-procedure and fvA (r 5 0.61; 
p < 0.01).
Conclusions: The MGHS is valuable in the selection of 
patients for PMBv, but fails to separate selected patients into 
prognostic groups. Assessment of chordal length provides 
useful additional information, predicting the outcome of 
PMBv more accurately. our data may support the earlier 
use of PMBv (asymptomatic patients). 
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Mitral stenosis (MS) is a mechanical disorder, with a natural 
history altered only by surgery or percutaneous balloon valvot-
omy.1,2 Medical management strategies are therefore viewed as 
adjunctive to further intervention when appropriate.
Mechanical intervention: The introduction of percutaneous 
transseptal mitral balloon valvotomy (PMBV) by Inoue and 
colleagues in 1984 gave a new option of treatment for patients 
with MS.3 In patients judged to have valve morphology suitable 
for a commissurotomy, several randomised trials have shown 
that balloon dilation gives results equivalent to open and closed 
surgical valvotomy, both short and long term.4-7 It has also 
proven to be a valuable therapeutic option in patients not fit to 
undergo mitral valve surgery.
Echocardiography is an essential non-invasive diagnostic 
procedure used to assess the severity of MS and to judge the 
feasibility of balloon valvotomy in a specific patient. To help 
predict which patients would have an optimal outcome after 
PMBV, several echocardiographic scoring systems have been 
developed. 
The Massachusetts General Hospital score (MGHS) is a 
widely used echocardiographic scoring system developed by 
Wilkins et al.8,9 It assigns a severity grade from 0 to 4 to each of 
the following valvular morphological and functional character-
istics: leaflet mobility, leaflet thickening, valvular calcification 
and subvalvular disease (ie, degree of chordal thickening). A 
high score (> 8 is associated with a lower immediate success 
rate and a higher rate of restenosis. Evaluation is done using 
precordial transthoracic echocardiography. This is also the scor-
ing system currently in use at our cardiology department.
The ability of the MGHS to separate individual patients 
selected for PMBV into different prognostic groups appears to 
be limited.9 Echocardiographic underestimation of the sever-
ity of subvalvular involvement may contribute to the failure to 
identify a subgroup of patients who are at risk of a less-than-
optimal outcome and/or development of significant mitral 
regurgitation.10
The aim of our study was to identify those features of the 
mitral valve apparatus that would allow better selection of 
patients, increasing the proportion of patients with a successful 
outcome. We emphasised assessment of the subvalvular appara-
tus, focusing on chordal length as a predictor of outcome. 
Transoesophageal echocardiography has been shown to 
provide a more accurate diagnostic evaluation of the mitral 
valve apparatus, an approach that is not currently used prior to 
PMBV for this specific purpose.11,12 We have therefore included 
combinations of different echocardiographic views in evaluating 
the subvalvular apparatus in our study.
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Patients and methods
A cohort study was done at the Cardiology Department of 
Tygerberg Hospital, University of Stellenbosch. A protocol 
was submitted to and approved by the ethics committee of the 
University of Stellenbosch. All patients consented to the study 
protocol, which included a description of the procedure. The 
study was conducted in accordance with the Declaration of 
Helsinki.
Between January 2002 and December 2003, 39 patients with 
symptomatic MS underwent PMBV. They had moderate/severe 
MS (valve area of ≤ 1.5 cm² or mean transvalvular gradient of > 
12 mmHg), a MGHS of < 10, no or mild MR and no contraindi-
cation to proceed with PMBV.
Prior to undergoing PMBV, all patients had repeat echocar-
diographic evaluation with two-dimensional and Doppler stud-
ies, using a Hewlett Packard Series 2000 ultrasound scanner. 
A 2.0/2.5-MHz probe and Hewlett Packard omni-plane probe 
were used for transthoracic, transoesophageal and transgastric 
views.
Standard two-dimensional transthoracic echocardiographic 
images were obtained in the parasternal long- and short-axis 
views and the apical four-chamber and long-axis views. Mitral 
valve area was calculated by direct two-dimensional planimetry. 
The resting mean pressure gradients across the mitral valve, as 
well as pulmonary artery pressure were recorded. Mitral valve 
morphology was scored as described by Wilkins and colleagues 
in the MGHS with a maximum score of 16.8 The left ventricu-
lar length (mm) was measured at the end of diastole using the 
apical four-chamber view.
The left atrium was evaluated using transoesophageal echo 
for the presence of thrombi, a possible contraindication for 
PMBV.13 The degree of commissural fusion was assessed as 
mild, moderate or severe.
The subvalvular apparatus was viewed using transgastric 
echocardiography in the long-axis gastric view. The length of 
the primary and secondary chordae tendineae was measured 
(mm) at the end of diastole (Fig. 1) and expressed as an absolute 
value as well as a ratio of left ventricular length.
Inoue percutaneous balloon mitral valvotomy was performed 
using the anterograde transseptal approach with a Brockenbrough 
needle (access via the femoral vein). The maximal nominal 
inflated balloon diameter was selected according to the patient’s 
height [height (cm) 4 10 1 10]. Balloon inflation was done in 
increments up to the maximal diameter. The end-point was an 
adequate transmitral gradient reduction or the development of 
significant mitral regurgitation. 
Assessment of results
Transthoracic echo and Doppler pressures were repeated post 
valvotomy. An immediate optimal result included: a final 
valve area of ≥ 1.5 cm² or ≥ 50% increase in mitral valve area. 
Significant complications were regarded as severe mitral regur-
gitation, pulmonary:systemic shunt ≥ 2:1 across the iatrogenic 
atrial septal defect, systemic embolism, cardiac tamponade and 
death. Clinical and echocardiographic follow-up were done 
over a one-year period with assessments repeated on day one, 
and one month, six months and 12 months after the procedure. 
Endpoints were significant mitral valve restenosis (repeat 
valvotomy or mitral valve replacement) and cardiac death. 
Statistical analysis
Results were expressed as mean (SD). Spearman correlations 
were calculated to compare continuous variables. The Kruskal-
Wallis test was used to determine significant differences 
between the means of different groups. Receiver operating 
characteristic (ROC) curves were used to determine the diag-
nostic ability of various measurements. A p-value < 0.05 was 
considered as statistically significant.
Results
Patient population and pre-procedural variables
The study population consisted of 39 patients, two male and 37 
female, with a mean (SD) age of 36 (13) years (range 23−78). 
Ten patients (26%) were pregnant at the time of intervention and 
four patients (10%) were known to have had previous valvoto-
mies. Four patients (10%) were in NYHA functional class I, 17 
(44%) in NYHA class II, 10 (26%) in NYHA class III and six 
(15%) in NYHA class IV. Atrial fibrillation was present in six 
patients (15%). In one patient an emergency PMBV was done. 
Chordal lengths were therefore not recorded in this patient. 
Echocardiographic features prior to PMBV are summarised in 
Table 1.
Clinical and echocardiographic follow-up
After a period of two years, one-month follow-up information 
was available for 34 (87%) patients, while 15 patients (38%) 
TABLE 1. ECHoCARDioGRAPHiC fEATuRES PRioR To PMBv
Variable MGHS
PAP
(mmHg) 
MVA 
(cm²)
Mean gradient 
(mmHg)
Anterior primary 
chordae (mm)
Anterior secondary 
chordae (mm)
Posterior primary 
chordae (mm)
Posterior secondary 
chordae (mm)
n 39 39 39 39 38 17 38 23
Mean 6.620 46.41 0.97 13.38 19.67 18.08 15.22 12.24
Std deviation 1.41 17.43 0.26 5.52 7.29 8.25 6.24 3.66
MGHS, Massachusetts General Hospital Score; MVA, mitral valve area; PAP, pulmonary artery pressure; PMBV, percutaneous mitral balloon 
valvotomy.
Fig. 1. Transgastric echo (long-axis gastric view): length 
of primary and secondary chordae tendineae (mm).
posterior
anterior
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had reached their 12-month follow-up date; six patients (15%) 
were lost to follow-up at the time (Table 2). Over the follow-up 
period, varying from one to 12 months, there were no deaths; 
one patient was referred for mitral valve replacement due to the 
development of severe mitral regurgitation with symptomatic 
deterioration.
Immediate outcome: Inoue balloon mitral valvotomy was 
performed in all patients. The mean (SD) mitral valve area 
increased from 0.97 (0.26) cm² to 1.52 (0.38) cm² and the mean 
(SD) transvalvular gradient decreased from 13.38 (5.52) mmHg 
to 6.43 (3.21) mmHg. Procedural success (either a final valve 
area of ≥ 1.5 cm² or a ≥ 50% increase in mitral valve area) 
was seen in 31 patients (79.5%) with a sub-optimal result in 
eight patients (20.5%). No immediate complications occurred. 
Mean (SD) pulmonary artery pressure was reduced from 46.41 
(17.43) mmHg to 40 (13.43) mmHg. 
Predictors of outcome
There was a poor correlation (r 5 0.09) between the MGHS 
and the final valve area achieved (Fig. 2a). When comparing 
the MGHS as a continuous variable with a final valve area of < 
1.5 cm² and ≥ 1.5 cm², there was no significant difference in the 
mean MGHS of these two groups (Fig. 2b; p 5 0.38).
A positive correlation (r 5 0.61; p < 0.01) was demonstrated 
between the initial mitral valve area and the final valve area 
achieved when compared as continuous variables (Fig. 2a). A 
final valve area of ≥ 1.5 cm² was also associated with a signifi-
cantly higher mean initial valve area (Fig. 2b; p < 0.01).
In evaluating the subvalvular apparatus, chordal lengths as 
continuous variables were correlated with the final valve area 
achieved. The four different chordae measured all showed a 
positive correlation with the final valve area (Fig. 3a). A final 
valve area of ≥ 1.5 cm² was also associated with higher mean 
chordal lengths (Fig. 3b). Expressing the chordal length as a 
ratio of left ventricular length, to correct for patient size, did not 
have any significant influence on the above results. 
In view of the positive correlations found between chordal 
length and the final valve area achieved, ROC curves were used 
to calculate the sensitivity and specificity of different chordal 
lengths to predict a final valve area of ≥ 1.5 cm². A posterior 
secondary chordal length of ≥ 12 mm predicted a final valve 
area of ≥ 1.5 cm² with a sensitivity of 70% and specificity of 
80% (Fig. 4), while the other chordal measurements did not 
contribute to the predictions.
TABLE 2. CLiNiCAL AND ECHoCARDioGRAPHiC  
foLLoW-uP
Pre-valvotomy 1 month 12 months
Mean NYHA class (SD) 2.36 (1.02) 1.54 (0.89) 1.2 (0.94)
Mean MVA (SD) (cm²) 0.96 (0.26) 1.52 (0.28) 1.54 (0.39)
Mean transvalvular 
gradient (SD) (mmHg)
13.38 (5.52) 6.51 (2.23) 5.55 (2.63)
Mean PAP (SD) 
(mmHg)
46.41 (17.43) 37.06 (11.26) 36.8 (11.03)
Severe MR 0 2 patients (6%) 0
MR, mitral regurgitation; MVA, mitral valve area; NYHA, New York 
Heart Association; PAP, pulmonary artery pressure.
Fig. 2a. Scatter plot of final valve area (cm²) vs MGHS 
and initial MVA (cm²), respectively.
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Fig. 2b. Average MGHS and initial MVA (cm²) in patients 
with a final valve area of < 1.5 and ≥ 1.5 cm², respectively. 
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Fig. 3a. Scatter plot of final valve area (cm²) vs chordae 
tendineae (mm). 
Fig. 3b. Average chordal lengths in patients with a final 
valve area of , 1.5 and ≥ 1.5 cm2, respectively. 
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Discussion
Mitral balloon valvotomy is a well-established nonsurgical 
alternative in the treatment of significant mitral stenosis. 
Although clinical variables are helpful in the initial identifica-
tion of patients who require intervention, the strongest inde-
pendent predictor of outcome in several studies has remained 
the morphological appearance of the mitral valve and the 
subvalvular apparatus.8,9
The use of an echocardiographic scoring system, the MGHS 
developed by Wilkins et al, has been accepted by most centres 
as an aid to patient selection, helping to predict both immediate 
and long-term outcomes.8,9 Our study confirms that the MGHS 
is valuable in the initial selection of patients who are likely to 
undergo an uncomplicated procedure with a successful outcome, 
seen in 31 (79.5%) of our 39 patients. The ability of the MGHS 
to predict a final valve area of ≥ 1.5 cm² in individual cases 
was, however, limited (Fig. 2b) and the correlation with the final 
valve area achieved was poor (r 5 0.09; Fig. 2a). This empha-
sises the limitations of the MGHS to separate selected patients 
into different prognostic groups. 
Thickening and shortening of the subvalvular apparatus has 
been shown to be associated with a sub-optimal outcome, often 
due to the development of mitral regurgitation.14-16 Evaluation 
of the subvalvular apparatus using the MGHS focuses mainly 
on the degree of chordal thickening. The correlation between 
pathological specimens (post mortem) and the echocardio-
graphic assessment is, however, poor.17 Underestimation of the 
severity of subvalvular involvement would contribute to the 
failure to identify a subgroup of patients who are at risk of a 
less-than-optimal outcome and/or development of significant 
mitral regurgitation.9,10
As a more objective evaluation of the subvalvular apparatus, 
we measured the length of each of the chordae tendineae and 
also expressed this as a ratio of the left ventricular length, to 
correct for patient size. The chordal lengths showed a corre-
lation with the final valve area achieved, with the anterior 
secondary chordae showing the strongest (r 5 0.66; p 5 0.01) 
and the posterior primary chordae the weakest (r 5 0.24; p 5 
0.15) correlation (Fig. 3a). A final valve area of ≥ 1.5 cm² was 
associated with longer chordae tendineae: a final valve area of < 
1.5 cm² was associated with a mean anterior secondary chordal 
length of 12.79 mm versus 20.75 mm seen in patients with a 
final valve area of ≥ 1.5 cm² (p 5 0.02; Fig. 3b). Expressing 
the chordal length as a ratio of left ventricular length rather 
than absolute length did not make a significant difference to the 
above results. 
Shortening of the chordae tendineae provides us with an 
objective echocardiographic measurement, reflecting the sever-
ity of subvalvular disease. Incorporation of chordal length in our 
future assessment of patients for PMBV by using an extended 
echocardiographic scoring system could improve the accuracy 
of selection of suitable patients.
Current indications for intervention (either PMBV or surgery) 
in patients with MS include moderate to severe MS (valve area 
< 1.5 cm²) in the presence of symptoms or, in the asymptomatic 
patient, significant pulmonary hypertension or pregnancy.18 
The positive correlation demonstrated in our study between 
the initial mitral valve area and the final valve area achieved 
(Fig. 2a; r 5 0.61; p < 0.01) as well as the significantly larger 
mean initial mitral valve area (Fig. 2b; p < 0.01) associated with 
a final valve area of ≥ 1.5 cm² are most likely explained by 
basic mathematical principles (ie, the larger the starting value, 
the larger the final value). However, it does raise the question 
whether PMBV shouldn’t be considered in the asymptomatic 
patient with moderate MS (mitral valve area of 1−1.5 cm²), 
even in the absence of significant pulmonary hypertension or 
pregnancy. Whether this initial successful outcome will translate 
into a sustained favourable clinical and haemodynamic outcome 
will require further evaluation in a prospective study. 
A relative small number of patients (39) were studied and 
the lack of complete data for all patients was a limitation. 
Visualisation of chordal structures requires optimal echocar-
diographic windows. Combinations of transgastric and transtho-
racic views were required in some patients to evaluate the chor-
dae accurately. In patients with severe damage to the subvalvular 
apparatus, the secondary chordae tendineae were not always 
identified, limiting the number of patients in the analysis.
Conclusions
Echocardiographic morphology, as described by Wilkins et 
al. in the MGHS, remains a valuable guide in our selection of 
patients suitable for PMBV. A final decision to perform the 
procedure in an individual patient should, however, include 
other considerations.
The length of the chordae tendineae provides an objective 
reflection of subvalvular disease, correlating with immediate 
outcome after PMBV. Although this feature has not been evalu-
ated as a lone predictor of outcome in the unselected patient, its 
addition to current scoring systems may allow better selection 
of patients (ie, identify patients at risk to have a sub-optimal 
result), aiding in the decision of medical versus surgical/inter-
ventional therapy in a selected individual. Future application of 
this echocardiographic information through the development of 
a new or additional scoring system could increase the proportion 
of selected patients with a successful outcome after PMBV. 
In view of the clear correlation found between the initial 
valve area and the final valve area achieved, future considera-
Fig. 4 A ROC curve using chordal length to predict a final 
valve area of ≥ 1.5 cm2. A posterior secondary chordal 
length of ≥ 12 mm has a sensitivity of 70% and specificity 
of 80% to predict a final valve area of ≥ 1.5 cm2.
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tion through prospective studies should be given to the earlier 
use of PMBV in asymptomatic patients with moderate MS 
before progression to more severe disease. 
We thank Drs M Carstens, H Cyster and M Kidd and Ms S Smith as well 
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